Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Hairy Cell Leukemia
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Leukemia (2149
)
Acute Myelogenous Leukemia (1006
)
Acute Lymphocytic Leukemia (418
)
Chronic Lymphocytic Leukemia (326
)
Chronic Myeloid Leukemia (267
)
B Acute Lymphoblastic Leukemia (193
)
T Acute Lymphoblastic Leukemia (39
)
Childhood B Acute Lymphoblastic Leukemia (37
)
Chronic Myelomonocytic Leukemia (20
)
Prolymphocytic Leukemia (17
)
Acute Promyelocytic Leukemia (12
)
Juvenile Myelomonocytic Leukemia (5
)
Chronic Eosinophilic Leukemia (4
)
Chronic Neutrophilic Leukemia (3
)
Leukemia (2149
)
Acute Myelogenous Leukemia (1006
)
Acute Lymphocytic Leukemia (418
)
Chronic Lymphocytic Leukemia (326
)
Chronic Myeloid Leukemia (267
)
B Acute Lymphoblastic Leukemia (193
)
T Acute Lymphoblastic Leukemia (39
)
Childhood B Acute Lymphoblastic Leukemia (37
)
Chronic Myelomonocytic Leukemia (20
)
Prolymphocytic Leukemia (17
)
Acute Promyelocytic Leukemia (12
)
Juvenile Myelomonocytic Leukemia (5
)
Chronic Eosinophilic Leukemia (4
)
Chronic Neutrophilic Leukemia (3
)
›
Associations
(23)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Hairy Cell Leukemia
No biomarker
Hairy Cell Leukemia
cladribine
Sensitive: A1 - Approval
cladribine
Sensitive
:
A1
cladribine
Sensitive: A1 - Approval
cladribine
Sensitive
:
A1
No biomarker
Hairy Cell Leukemia
No biomarker
Hairy Cell Leukemia
moxetumomab pasudotox
Sensitive: A1 - Approval
moxetumomab pasudotox
Sensitive
:
A1
moxetumomab pasudotox
Sensitive: A1 - Approval
moxetumomab pasudotox
Sensitive
:
A1
No biomarker
Hairy Cell Leukemia
No biomarker
Hairy Cell Leukemia
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
No biomarker
Hairy Cell Leukemia
No biomarker
Hairy Cell Leukemia
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
No biomarker
Hairy Cell Leukemia
No biomarker
Hairy Cell Leukemia
vemurafenib + rituximab
Sensitive: A2 - Guideline
vemurafenib + rituximab
Sensitive
:
A2
vemurafenib + rituximab
Sensitive: A2 - Guideline
vemurafenib + rituximab
Sensitive
:
A2
No biomarker
Hairy Cell Leukemia
No biomarker
Hairy Cell Leukemia
pentostatin
Sensitive: A2 - Guideline
pentostatin
Sensitive
:
A2
pentostatin
Sensitive: A2 - Guideline
pentostatin
Sensitive
:
A2
No biomarker
Hairy Cell Leukemia
No biomarker
Hairy Cell Leukemia
rituximab/hyaluronidase
Sensitive: A2 - Guideline
rituximab / hyaluronidase
Sensitive
:
A2
rituximab/hyaluronidase
Sensitive: A2 - Guideline
rituximab / hyaluronidase
Sensitive
:
A2
No biomarker
Hairy Cell Leukemia
No biomarker
Hairy Cell Leukemia
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
No biomarker
Hairy Cell Leukemia
No biomarker
Hairy Cell Leukemia
vemurafenib
Sensitive: A2 - Guideline
vemurafenib
Sensitive
:
A2
vemurafenib
Sensitive: A2 - Guideline
vemurafenib
Sensitive
:
A2
No biomarker
Hairy Cell Leukemia
No biomarker
Hairy Cell Leukemia
ibrutinib
Sensitive: A2 - Guideline
ibrutinib
Sensitive
:
A2
ibrutinib
Sensitive: A2 - Guideline
ibrutinib
Sensitive
:
A2
No biomarker
Hairy Cell Leukemia
No biomarker
Hairy Cell Leukemia
vemurafenib + obinutuzumab
Sensitive: A2 - Guideline
vemurafenib + obinutuzumab
Sensitive
:
A2
vemurafenib + obinutuzumab
Sensitive: A2 - Guideline
vemurafenib + obinutuzumab
Sensitive
:
A2
No biomarker
Hairy Cell Leukemia
No biomarker
Hairy Cell Leukemia
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
No biomarker
Hairy Cell Leukemia
No biomarker
Hairy Cell Leukemia
venetoclax + rituximab
Sensitive: A2 - Guideline
venetoclax + rituximab
Sensitive
:
A2
venetoclax + rituximab
Sensitive: A2 - Guideline
venetoclax + rituximab
Sensitive
:
A2
No biomarker
Hairy Cell Leukemia
No biomarker
Hairy Cell Leukemia
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
BRAF V600E
Hairy Cell Leukemia
BRAF V600E
Hairy Cell Leukemia
dabrafenib
Sensitive: C2 – Inclusion Criteria
dabrafenib
Sensitive
:
C2
dabrafenib
Sensitive: C2 – Inclusion Criteria
dabrafenib
Sensitive
:
C2
BRAF V600
Hairy Cell Leukemia
BRAF V600
Hairy Cell Leukemia
vemurafenib
Sensitive: C2 – Inclusion Criteria
vemurafenib
Sensitive
:
C2
vemurafenib
Sensitive: C2 – Inclusion Criteria
vemurafenib
Sensitive
:
C2
BRAF V600E
Hairy Cell Leukemia
BRAF V600E
Hairy Cell Leukemia
vemurafenib
Sensitive: C2 – Inclusion Criteria
vemurafenib
Sensitive
:
C2
vemurafenib
Sensitive: C2 – Inclusion Criteria
vemurafenib
Sensitive
:
C2
BRAF V600E
Hairy Cell Leukemia
BRAF V600E
Hairy Cell Leukemia
vemurafenib + rituximab
Sensitive: C2 – Inclusion Criteria
vemurafenib + rituximab
Sensitive
:
C2
vemurafenib + rituximab
Sensitive: C2 – Inclusion Criteria
vemurafenib + rituximab
Sensitive
:
C2
BRAF V600E
Hairy Cell Leukemia
BRAF V600E
Hairy Cell Leukemia
dabrafenib + rituximab
Sensitive: C3 – Early Trials
dabrafenib + rituximab
Sensitive
:
C3
dabrafenib + rituximab
Sensitive: C3 – Early Trials
dabrafenib + rituximab
Sensitive
:
C3
TP53 mutation
Hairy Cell Leukemia
TP53 mutation
Hairy Cell Leukemia
rituximab + cladribine
Resistant: C3 – Early Trials
rituximab + cladribine
Resistant
:
C3
rituximab + cladribine
Resistant: C3 – Early Trials
rituximab + cladribine
Resistant
:
C3
BRAF V600E
Hairy Cell Leukemia
BRAF V600E
Hairy Cell Leukemia
trametinib + dabrafenib
Sensitive: C3 – Early Trials
trametinib + dabrafenib
Sensitive
:
C3
trametinib + dabrafenib
Sensitive: C3 – Early Trials
trametinib + dabrafenib
Sensitive
:
C3
MYD88 L265P + BRAF V600E
Hairy Cell Leukemia
MYD88 L265P + BRAF V600E
Hairy Cell Leukemia
rituximab
Sensitive: C4 – Case Studies
rituximab
Sensitive
:
C4
rituximab
Sensitive: C4 – Case Studies
rituximab
Sensitive
:
C4
KRAS mutation
Hairy Cell Leukemia
KRAS mutation
Hairy Cell Leukemia
vemurafenib
Resistant: C4 – Case Studies
vemurafenib
Resistant
:
C4
vemurafenib
Resistant: C4 – Case Studies
vemurafenib
Resistant
:
C4
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login